Unicycive reports 2022 net loss of $18.1M, cash $0.5M; closes $30M fundraise; NDA on track for mid-2023

Unicycive Therapeutics, Inc.

2023-Q1 EPS reported -$0.97 revenue$675,000

Net loss for 2022 was $18.1M ($1.20/sh) vs $10.0M ($0.86/sh) in 2021.
Cash and equivalents $0.5M at Dec 31, 2022; closed $30M private placement with up to $130M total.
Renazorb pivotal BE study met primary endpoint; NDA submission on track for mid-2023.
Exclusive license with Lotus Pharma for Renazorb in South Korea.
R&D expenses $12.4M (up 103% YoY) driven by $6.5M in development services.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Unicycive Therapeutics, Inc. reported financial results for full year ended December 31, 2022.

Period: full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 31, 2023, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2022 and provided a business update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-024969

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.